Clinical Trial Update: DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC [Phase 1]

View source ↗

Summary

A Phase 1 trial named DAPHNe is evaluating the combination of paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer. The study is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING